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Natural Cycles: When an Algorithm Digitally
Mandates Your Sexual Health
Jacqueline Tran*
I. INTRODUCTION
Contraception has been materialized in a variety of forms—pills, t-
shaped plastic, and even nothing at all—so, in this technology-driven world,
is it really a surprise that contraception would be delivered through our
phones? Apparently not. In 2017, a Swedish start-up introduced the world to
Natural Cycles, the first mobile application to be CE-marked1 in Europe as a
Class IIb medical device to be used as a method of contraception.2 This past
August, the U.S. Food and Drug Administration (FDA) classified Natural
Cycles as a Class II medical device and cleared the mobile application for
marketing in the United States as a method of contraception.3 By embodying
a fertility-awareness-based (FAB) method of contraception, Natural Cycles
advertises itself as a hormone-free, noninvasive option for women intending
to prevent or plan a pregnancy.4 Despite the array of existing mobile applica-
tions that assist women who choose this method of contraception, Natural
Cycles is the only mobile application to break through the convoluted market
as a medical device that attempts to navigate consumers through the not-so-
simple journey of fertility awareness.5
Fertility awareness, and using FAB methods of contraception, revolves
around the basic principle of women monitoring their ovulation cycles to
determine their highest chances of conception in order to either plan or pre-
* Jacqueline Tran is a 2020 candidate for Juris Doctor from SMU Dedman
School of Law. She received a Bachelor of Science Degree in Health Promoo-
tion and Disease Prevention from the University of Southern California in
2015. Jacqueline would like to thank her family for supporting her in all of her
endeavors in law school and being her pillar throughout the entirety of this case
note writing process.
1. A certification mark that indicates conformity with health, safety, and environ-
mental protection standards.
2. Quality Assured & Recognised, NAT. CYCLES, https://www.naturalcycles.com/
en/science/certifications/ (last visited Aug. 26, 2019).
3. See id.; see also Press Release, U.S. Food & Drug Admin. (Aug. 10, 2018) (on
file with author).
4. See E. Berglund Scherwitzl et al., Perfect-Use and Typical-Use Pearl Index of
a Contraceptive Mobile App, 96 CONTRACEPTION 420, 420–21 (2017); see also
Is Natural Cycles the Birth Control Method for Me?, NAT. CYCLES, https://
www.naturalcycles.com/birthcontrol/is-natural-cycles-for-me (last visited Aug.
26, 2019).
5. See Nicole Wetsman, Why You Should Not Trust Fertility Apps—Yet, SLATE
(Sept. 19, 2018), https://slate.com/technology/2018/09/fertility-apps-birth-con-
trol-evidence.html.
180 SMU Science and Technology Law Review [Vol. XXII
vent pregnancy.6 When monitored diligently and accurately, traditional FAB
methods can be an effective way to replace hormonal intake. However, these
methods may not transfer as well into a digital form, although many mobile
applications have tried.7 Natural Cycles joins the likes of Daysy, an existing
FAB mobile application, in the way they both track fertility, yet Natural Cy-
cles differs drastically by being able to advertise itself as an actual method of
contraception.8 After paying an annual or monthly fee,9 a Natural Cycles cus-
tomer receives a basal thermometer, used every morning to directly measure
the woman’s temperature and indirectly measure the woman’s hormone
levels to provide data that is entered into the mobile application.10 The mo-
bile application then utilizes an algorithm to analyze the thermometer read-
ings and the woman’s manual input of her period data to determine whether
the woman is likely to be fertile.11 From there, the application emits a red or
green display to indicate the likelihood of ovulation, giving the woman gui-
dance on how to proceed with her sexual activity for the day.12 Due to the
sensitive nature of these readings, Natural Cycles notes that the “Instructions
for Use” must be adhered to carefully in order to reach the desired results of
perfect use and also notes examples of factors that could affect a woman’s
basal body temperature and potentially fluctuate the application’s output.13
Critics have found this point to be unsettling because this FAB method of
contraception conveyed through this digitalized medium seems to simplify
the hard work and patience that is traditionally invested by women who
choose to engage in the complexities of fertility awareness.14
As noted, it is not uncommon to find mobile applications that assist
women in their efforts to participate in fertility awareness, yet Natural Cycles
differentiated itself through the successful obtainment of a CE-mark in Eu-
rope and FDA clearance for marketing in the United States.15 Natural Cycles
was able to accomplish this by closing the existing gap, a lack of scientific
research and backing in nearly all FAB applications, through its own pro-
6. See id.
7. See id.
8. See Technology, DAYSY, https://usa.daysy.me/technology/ (last visited Aug. 26,
2019); How it Works, NAT. CYCLES, https://www.naturalcycles.com/en/contra-
ception/howitworks/ (last visited Aug. 26, 2019).
9. Sign Up, NAT. CYCLES, https://www.naturalcycles.com/en/signup (last visited
Aug. 26, 2019).
10. How it Works, supra note 8.
11. See id.
12. See id.
13. Frequently Asked Questions, NAT. CYCLES, https://www.naturalcycles.com/
faqs (last visited Aug. 26, 2019).
14. See Wetsman, supra note 5.
15. See Quality Assured & Recognised, supra note 2.
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spective study.16 This study served as the basis that propelled Natural Cycles
forward as a mobile application that could be legitimately considered by the
FDA, especially during a time when the FDA’s efforts have been concen-
trated on digital health innovations.17 However, from this standpoint, the
FDA’s approval process seems rather basic, and critics are skeptical of the
standards used to evaluate Natural Cycles’ study in light of the FDA’s goals
for digital health.18 Additionally, it is unclear whether or not consumers are
aware of the varying classifications of medical devices and the processes
used to classify each device. Because Natural Cycles was tagged as a novel
device with low-to-moderate risk, it was given automatic classification as a
class III medical device with subsequent classification into class II after a de
novo classification request and review.19 This classification and approval
process for Natural Cycles has acted as a jumping-off point from which the
FDA aims to build off of and develop a new regulatory classification,
“software application for contraception,” for similar devices to more swiftly
go through the 510(k) process.20 As noted in the FDA’s Digital Health Inno-
vation Action Plan, a relaxed 510(k) process is one of the several initiatives
the FDA seeks to accomplish in order to decrease submission content and
produce faster reviews of marketing submissions for certain digital health
products.21 Although efficiency is almost always seen as a positive in today’s
world of immediate gratification, a rapid evaluation of devices similar to
Natural Cycles may not be the appropriate way to test this newer, lenient
process. The FDA’s approval process for this type of medical device may
negatively impact consumers who have not been properly educated on the
variety of approval levels and those who do not understand the implications
of an “FDA approved” or “FDA cleared” device beyond what is conveyed to
them through their phone screen.22
16. See Scherwitzl et al., supra note 4, at 420; see also Wetsman, supra note 5.
17. See Digital Health Innovation Action Plan 1, U.S. FOOD & DRUG ADMIN.
(2017) https://www.fda.gov/MedicalDevices/DigitalHealth/.
18. Katie Brigham, Fertility Apps are Increasingly Being Used as Contraception
and One Has Even Gained FDA Approval, CNBC (Oct. 13, 2018), https://www
.cnbc.com/2018/10/13/fertility-apps-are-one-the-rise-and-natural-cycles-is-
now-fda-approved.html.
19. See Letter from Angela C. Krueger, Deputy Dir., Ctr. for Devices & Radiologi-
cal Health, to Sheila Hemeon-Heyer, President & Founder, Heyer Regulatory
Sols. (Aug. 10, 2018) (on file with the author); see also Press Release, supra
note 3.
20. See Letter from Angela C. Krueger, supra note 19.
21. See Digital Health Innovation Action Plan 1, supra note 17, at 2, 4–5.
22. David McNamee, How Does the FDA ‘Approve’ Medical Products?, MED.
NEWS TODAY (Feb. 20, 2014), https://www.medicalnewstoday.com/articles/
272986.php.
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II. LEGAL BACKGROUND
Concerns, and the need to address them, are arising in response to the
positive movement forward by the FDA in regulating digital health technol-
ogy.23 The FDA’s Digital Health Innovation Action Plan, released in 2017,
recognized the need for a restructuring to better address the health technol-
ogy that was developing in our nation.24 Part of this plan was an acknowl-
edgement of what has been in the works, as well as an effort to build off of
those accomplishments to bring forth more policies into fruition.25 One of the
needs the FDA has been working to meet is one of digital health oversight,
which was originally addressed through the creation of a “Digital Health Pro-
gram.”26 This program has been streamlining oversight of mobile medical
applications that present a higher risk to patients and continues to impose
more lenient compliance for the ones deemed a lower risk.27 To do so, the
FDA relies on a 510(k) premarket notification process that approves Class I,
II, or III devices for marketing without requiring a Premarket Approval
(PMA).28 Although the FDA may meet its goal of delivering more health
technology to consumers at a faster rate through this streamlined process, it
may be doing so at the risk of conducting insufficient testing and releasing
unsafe or ineffective products into the market.29
The level of scrutiny drops when evaluating Class III down to Class II
devices and is reflected in the processes in place for evaluating these devices
for clearance or approval.30 There are two heavily used forms of FDA
premarket submissions: the 510(k) premarket notification and the PMA.31
The PMA process is specific to evaluating only Class III medical devices for
approval and adheres to the most stringent evaluation, including a submission
of clinical trials, due to the higher risk levels of these types of devices.32 In
contrast, a 510(k) is submitted for any device class that is intended for human
use, and these devices only need to convince the FDA of their substantial
equivalence to an existing legally marketed device before being cleared for
23. See id.
24. See Digital Health Innovation Action Plan 1, supra note 17, at 1–2.
25. See id. at 2–3.
26. Id. at 2.
27. See id.
28. Premarket Notification 510(k), U.S. FOOD & DRUG ADMIN., https://www.fda
.gov/medical-devices/premarket-submissions/premarket-notification-510k (last
visited Aug. 26, 2019).
29. McNamee, supra note 22.
30. See id.
31. FDA Submissions, KEN BLOCK CONSULTING, https://kenblockconsulting.com/
fda-submissions (last visited Aug. 26, 2019).
32. See id.
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marketing.33 If the FDA determines that a device is not substantially
equivalent, the device may be submitted for a de novo review—the clearance
pathway that was taken by Natural Cycles.34 This de novo pathway is a “risk-
based classification process” that the FDA undertakes in evaluating the
safety and efficacy of a novel device, making a determination of the general
or special controls that need to be in place before the specific device can be
given clearance.35 From there, the devices that have been cleared through the
de novo pathway act as predicates for future, similar devices that are submit-
ted through a 510(k) premarket notification process.36
The differences between PMA and 510(k) go beyond the device review
process undertaken by the FDA.37 Though the review process is significant
on a regulatory level, the language used thereafter in addressing and market-
ing the product impacts consumers in their most integral choices.38 On the
most basic level, when a device receives PMA, that product is then entitled to
the label nearly all consumers are familiar with: “FDA approved.”39 In con-
trast, when a device receives 510(k) clearance, it can be referred to as “FDA
cleared,” “FDA listed,” or even “FDA registered.” These are not the same as
“FDA approved.”40 Labeling in this manner may not seem significant to con-
sumers, because most are under the impression that it all amounts to the same
result: that the FDA reviewed a product and found it to be safe and effective.
Unfortunately, this is not the case. The differences between the PMA and
510(k) processes are drastic enough that there is language in § 807.97 of the
Code of Federal Regulations to note the severe issue of misbranding.41 Sec-
tion 807.97 explicitly notes that “submission of a premarket notification . . .
does not in any way denote official approval of the device.”42 The language
of the statute offers a jarring look at the contrast that exists between the
literal text of the regulation and consumers’ perception of what approval
from the FDA really means. The FDA’s new regulatory classification will
put a host of devices at odds with § 807.97 and may present an issue to
manufacturers when determining the language to utilize when marketing to
consumers. Even if manufacturers were to abide by the basic language stan-
33. Id.
34. See Letter from Angela C. Krueger, supra note 19.
35. FDA Evaluation of Automatic Class III Designation (De Novo), U.S. FOOD &
DRUG ADMIN., https://www.fda.gov/medical-devices/premarket-submissions/




39. McNamee, supra note 22.
40. Id.
41. 21 C.F.R. § 807.97 (2019).
42. Id.
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dards and correctly label a 510(k) cleared device as “FDA cleared,” it contin-
ues to pose a risk to consumers because of the perceptions the labels hold.43
Because perceptions may be difficult to alter, it is useful to review the under-
lying need for the burden to shift onto the FDA to do something instead.
III. DEVELOPMENTS AND PROBLEMS
A. International Ramifications and Basis of Approval
First, the level of scrutiny administered by the FDA when reviewing a
mobile application for clearance must be considered in the context of its sci-
entific backing and how that may impact consumers based on their percep-
tions of traditional marketing language of these types of mobile applications.
The recent stir of Natural Cycles is derived not only from the innovative
aspect of the mobile application and being cleared by the FDA, but also, as
critics will point out, the international scrutiny that has been clouding its
name for months prior to the FDA’s press release in August 2018.44 After
being CE-marked in Europe in 2017, Natural Cycles came under fire when a
Swedish Hospital reported thirty-seven unwanted pregnancies resulting from
patients’ relying on the mobile application to prevent pregnancy.45 Addition-
ally, a formal investigation regarding Natural Cycles and its marketing was
launched by the United Kingdom’s Advertising Standards Authority (ASA)
after they received complaints about a misleading July 2017 paid-for-post
advertisement on Facebook.46 Although Sweden’s Medical Products Agency
recently cleared Natural Cycles for use, the United Kingdom’s ASA con-
cluded that the language used in Natural Cycles’ Facebook advertisement
was misleading.47 Despite the international activity surrounding Natural Cy-
43. See McNamee, supra note 22; see also Anna Altman, The Unlikely Politics of a
Digital Contraceptive, THE NEW YORKER (Oct. 2, 2018), https://www.newyork
er.com/tech/annals-of-technology/the-unlikely-politics-of-a-digital-contracep
tive.
44. Kate Sheridan, Controversial Contraception App Approved in U.S. Drawing
Scrutiny Overseas, STAT (Sept. 11, 2018), https://www.statnews.com/2018/09/
11/contraception-app-natural-cycles-scrutiny-sweden/.
45. See Dave Muoio, Another Regulatory Investigation Launched Against Natural
Cycles Contraceptive App, MOBI HEALTH NEWS (Aug. 2, 2018), https://www
.mobihealthnews.com/content/another-regulatory-investigation-launched-
against-natural-cycles-contraceptive-app.
46. Maev Kennedy, Natural Cycles: ASA Investigates Marketing for Contraception
App, THE GUARDIAN (July 29, 2018), https://www.theguardian.com/technol-
ogy/2018/jul/29/natural-cycles-asa-investigates-marketing-for-contraception-
app.
47. Kimberly Leonard, Swedish Authorities Clear “Natural Cycles” Birth Control
App, WASH. EXAMINER (Sept. 13, 2018), https://www.washingtonexaminer
.com/policy/healthcare/swedish-authorities-clear-natural-cycles-birth-control-
app (finding that the thirty-seven unwanted pregnancies out of the 668 women
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cles prior to the FDA’s press release, the FDA continued with its clearance of
the mobile application for marketing, finding the clinical trials and prospec-
tive study sufficient to meet its standards.48 When evaluating Natural Cycles’
study, critics note how poorly it was conducted and express their concerns
regarding the circumstances under which it was promulgated.49 For example,
not only was the research funded by the company, but also two out of the six
authors of the study are also the co-founders of Natural Cycles.50 Granted,
though there may not be any hard-and-fast rules against co-authoring a study
for a business you own, it does raise principled questions that critics use to
scrutinize the FDA’s decision to proceed without more inquiry. The skepti-
cism around the scientific backing of Natural Cycles derives from the ex-
isting uncertainty of dealing with fertility awareness digitally, a notion that
strays away from the more formalized methods that typically require more
time and money.51 A 2016 report that reviewed the various mobile applica-
tions available to track fertility exemplified the lack of reliable evidence
proving a mobile application’s ability to prevent pregnancy as well as the
host of factors that may interfere with a basal body temperature reading, such
as poor sleep, stress, alcohol, or even forgetfulness, which would ultimately
affect the output given for the day.52 Because there are many more factors
that may play a part in the dictation of a Natural Cycles’ reading, there is a
who had abortions at that hospital was in line with the 7% unintended preg-
nancy rate claimed by Natural Cycles based on typical use.); ASA Ruling on
NaturalCycles Nordic AB Sweden t/a Natural Cycles, ADVERT. STANDARDS
AUTH. (Aug. 29, 2019), https://www.asa.org.uk/rulings/naturalcycles-nordic-
ab-sweden-a17-393896.html (holding that the statement “Natural Cycles is a
highly accurate, certified, contraceptive app that adapts to every woman’s
unique menstrual cycle. Sign up to get to know your body and prevent
pregnancies naturally,” in conjunction with “Natural Cycles officially offers a
new, clinically tested alternative to birth control methods,” is misleading be-
cause claims were based on the perfect-use results even though the relevant
data of effectiveness should have been pulled from typical use).
48. See Altman, supra note 43.
49. See Wetsman, supra note 5 (noting Frank-Herrmann’s comment in the Euro-
pean Journal of Contraception & Reproductive Health Care criticizing how the
study calculated the “perfect use” rate inappropriately and how the “precision
and accuracy of the algorithm . . . use[d] to identify the day of ovulation . . . has
not been established”).
50. See Scherwitzl et al., supra note 4, at 420.
51. See Wetsman, supra note 5.
52. See Marguerite Duane et al., The Performance of Fertility Awareness-Based
Method Apps Marketed to Avoid Pregnancy, 29 J. AM. BD. FAM. MED. 508,
511 (2016); see Wetsman, supra note 5; see also Starting Natural Cycles,
supra note 13.
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high risk of human error that could occur.53 When a mobile application is a
woman’s sole source of pregnancy prevention, the guidance it provides is
crucial because an erroneous reading may lead to an unwanted pregnancy,
which is not a small incident for which to be at risk.54 Unintended
pregnancies bring with them health and financial risks that can negatively
pervade a woman’s life. Thus, critics are apprehensive about the ease with
which Natural Cycles was cleared by the FDA since the extent of the re-
quired disclosures to the public are minimal.55
B. FDA Review Processes
Because Natural Cycles is the most current and leading example of a
Class II medical device that has gone through the 510(k) premarket notifica-
tion process, it acts as the exemplary device for the FDA in dealing with
future contraceptive medical devices in the form of a mobile application.
Natural Cycles represents the future of contraception and, more generally,
the digitalization of women’s health to such a progressive extent so as to
involve the FDA.56 Although mobile applications such as Daysy have existed
as fertility tracking devices for some time, none have successfully reached
the point of obtaining FDA clearance.57 This is the crux of the matter. While
both fertility awareness as a natural method of contraception and mobile ap-
plications providing guidance for fertility awareness (even with the utiliza-
tion of a thermometer) have existed, never before has a mobile application
broken through the market as an FDA-recognized method of contraception.58
This breakthrough is surely indicative of the future of health, and the FDA
has exemplified its efforts in preparing for the transition, acknowledging the
likelihood that the transition will not be gradual in any sense.59 Although the
Digital Health Innovation Plan was created and developed with the intention
53. Caroline Criado Perez, Pregnancy is Riskier than Skydiving – Birth Control
Should be Harder to Market, CNN (Sept. 20, 2018), https://www.cnn.com/
2018/09/20/opinions/natural-cycles-pregnancy-skydiving-caroline-opinion-intl/
index.html.
54. See Olivia Sudjic, ‘I Felt Colossally Naive’: The Backlash Against the Birth
Control App, THE GUARDIAN (July 21, 2018), https://www.theguardian.com/
society/2018/jul/21/colossally-naive-backlash-birth-control-app.
55. Criado Perez, supra note 53 (stating that the FDA’s only specification for Nat-
ural Cycles was that their advertisements be clear about potential risks by in-
cludes “a statement that no contraceptive method is 100% effective”).
56. Nichi Hodgson, Natural Cycles May Be Flawed, but Contraception Apps are
Still the Future, THE GUARDIAN (Aug. 31, 2018), https://www.theguardian
.com/commentisfree/2018/aug/31/natural-cycles-tech-contraception-condoms-
coil-pill-birth-control.
57. See Wetsman, supra note 5.
58. See generally id.
59. See Hodgson, supra note 56.
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of combatting the burdens to come from digitalizing health, it may not be as
prepared for the realities of consumers intaking “birth control” through a
mobile application.60
This digital age has given us the advantage of having readily accessible
information at our fingertips and thus pushes consumers towards self-educa-
tion on the existing resources for self-investment. Thus, it could be argued
that the responsibility predominantly lies in the consumers to evaluate their
options and make an informed decision.61 However, in order for consumers
to truly make an informed decision, they will continue to rely on the stan-
dards in place to guide them in the right direction, which is one of the pur-
poses of the existence of our federal agencies. Consumers rely on the FDA
and its processes to aid them in making those informed decisions about prod-
ucts, drugs, or devices they choose for their daily life.62 To most consumers,
the FDA imposes a presupposition of safety, efficacy, and security, and may
be the reason why a consumer will choose one product over another.63 Be-
cause so much weight may be put on the successful functionality of the FDA,
it is important that consumers understand the approval process and the impli-
cations of the language used. However, the burden of education cannot be
wholly placed on consumers. Thus, it may be necessary that stricter
processes be put into place for certain devices, such as medical mobile
applications.
Once a device has crossed the 510(k) threshold for FDA clearance, there
are already preexisting issues of a consumer’s melded understanding of ap-
proval given by the PMA process versus clearance provided by a premarket
notification of 510(k).64 Unless a consumer is involved in, or particularly
curious about, the practice industry, most consumers do not keep themselves
apprised of the nuances within FDA regulations.65 Rather, they have a gener-
alized understanding and will likely infer a large degree of approval, safety,
and efficacy from the marketing language used for these devices, despite the
discrepancies in wording for these varying devices.66 In this digital era, there
is an over-reliance on mobile applications for their efficiency and functional-
ity without a complete awareness about the motivation and discipline needed
to achieve the “perfect use” that results in that 99% effective rate that is
60. See Digital Health Innovation Action Plan 1, supra note 17.
61. See generally Hodgson, supra note 56.
62. See McNamee, supra note 22.
63. See FDA Mission, U.S. FOOD & DRUG AMIN., https://www.fda.gov/aboutfda/
whatwedo/ (last visited Aug. 27, 2019).
64. Amie C. O’Donoghue et al., Consumers’ Understanding of FDA Approval Re-
quirements and Composite Scores in Direct-to-Consumer Prescription Drug
Print Ads., 21 J. HEALTH COMMC’N 927, 934 (2016).
65. See id.
66. See id.
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comparable to substantiated contraception methods.67 The mediums that are
used to advertise mobile applications are under little to no regulation and
pose issues in a consumer’s journey to informed consent when the social
interaction piece of obtaining a traditional form of contraception is removed
from the Natural Cycles process. Without knowing the depths of the FDA’s
approval process, consumers may mistake marketing that includes basic FDA
approval language as an all-encompassing “OK” to move forward. Consum-
ers may operate under the assumption that anything that is marked “FDA
Approved” has undergone the complete and necessary testing requirements
that warrant a safe and minimally risky product.68 With this kind of presump-
tion going into making decisions regarding sexual health, women are at risk
of making these crucial decisions on an incomplete knowledge base.
Currently, the rate at which our nation is advancing technologically
poses points of conflict for medical devices that are administered through
mobile applications.69 Accessibility is a double-edged sword. Not only is it
key to moving our nation forward in digital health by reaching consumers in
ways that were not possible fifteen years ago, but, by reaching consumers so
quickly, the increased level of marketing may lead to consequences that we
have not yet considered or for which we have not properly prepared.70 With
the introduction of social media outlets such as Facebook and Instagram,
there has been a new wave of marketing through “influencers” who provide a
type of advertising that takes the messaging of a product to a completely
unforeseen level.71 Specifically, the messaging of contraception through digi-
tal channels may invite more scrutiny than experienced in the past because of
the pervasiveness of the internet. When an innovative method of contracep-
tion like Natural Cycles enters the market and targets a more modern market-
ing approach, it is perceived as the new and flashier product when compared
to the tried and true “older” methods of contraception.72 When companies
utilize social media or “influencers” as a primary source for their marketing,
they condense information about the device into easy-to-read snippets or
thirty-second videos. It is therefore difficult to comprehend how enough ac-
curate information can reach the consumer in those quick advertisements for
her to make a fully informed decision. It seems as though there is a presump-
tion on the part of the company that these consumers will complete their due
diligence through further research of a device in which they are interested.73
This is a weighty presumption to place onto consumers. As healthcare con-
67. See Criado Perez, supra note 53.
68. Wetsman, supra note 5.
69. See Criado Perez, supra note 53.
70. See generally Hodgson, supra note 56; Wetsman, supra note 5.
71. Criado Perez, supra note 53.
72. See Criado Perez, supra note 53; see also Wetsman, supra note 5.
73. See generally Criado Perez, supra note 53.
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tinues to become commercialized,74 the overarching goals of Natural Cycles
as a company, and others that will mirror it in the years to come, will always
be questioned as the struggle subsists between making money and helping
others. But how much help are consumers really receiving from a mobile
application like Natural Cycles that pushes all of the real work onto the user?
Or, for that matter, from a federal agency that has the people’s best interest at
heart yet conducts the minimum evaluation for a Class II device that nor-
mally goes through a more rigorous review process?
Despite the flaws that critics find in the FDA’s current review process
for digital devices, the FDA has been able to track its objectives outlined in
the Digital Health Innovation Plan by beginning to provide lighter review
standards for innovative devices such Natural Cycles.75 Advocates for Natu-
ral Cycles find that innovation in this area is warranted as a step in the right
direction for expanding women’s right to make their own reproductive health
choices. This expansion of reproductive choice is essential in keeping up
with the technological advancements that are constantly occurring in this na-
tion. By digitalizing reproductive health in this way, Natural Cycles has been
able to increase efficiency, cut costs, and make contraception available to a
wider range of women who would not otherwise have access to contraception
at all.76 Reproductive choice has been a longstanding conversation and there-
fore there may be constitutional issues shrouding the push for stricter FDA
regulations in regard to the review and marketing of these digital devices.
C. Constitutional Implications
Reasonable solutions, such as a reevaluation of the approval processes
in place or more stringent marketing regulations, have been suggested to ad-
dress the rising concerns of the implied risks connected with marketing for a
mobile application like Natural Cycles.77 These solutions bring in a sense of
more federal involvement in the area of women’s health and choice, which
unearths sensitive issues of federal overreach in the constitutionally protected
areas of privacy, a right that has been consistently discussed since the mid-
1900s.78 The Fourteenth Amendment acts as the basis for the constitutional
implications that may arise if critics were to further advocate for more strin-
gent rules around the clearance of these mobile applications as it pertains to
contraception.79 Although there does not exist an express constitutional right
to birth control,80 the right to reproductive choice is rooted in precedent, his-
74. See Altman, supra note 43.
75. See generally Digital Health Innovation Action Plan 1, supra note 17.
76. See generally Hodgson, supra note 56.
77. See McNamee, supra note 22.
78. See Griswold v. Connecticut, 381 U.S. 479, 494–99 (1965).
79. See generally U.S. CONST. amend. XIV.
80. See id.
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tory, and tradition.81 Specifically, this right to reproductive choice can be
derived from the fundamental, unenumerated right of privacy found in Gris-
wold v. Connecticut.82 It has not been a simple task to get to the point of open
discussion and advocation for these fundamental, unenumerated rights such
as reproductive choice.83 Those decisions by the United States Supreme
Court paved the way for things such as “FemTech” to be seriously consid-
ered in today’s context. As a result, it is sensible that these persisting rights
be protected from the scrutinization of any government agency. On these
bases, advocates find that more stringent FDA regulations would only be
taking a step back in the progressive accomplishments reached as well as a
degrading of the existing freedom of reproductive choice, something that can
still be considered freshly decided in our judicial history.84
IV. CONCLUSION
The first-ever FDA cleared mobile application to disrupt the existing
market of contraception certainly causes critics and advocates alike to have
an opinion about how this product should proceed and the implications in
doing so. The international conversation revolving around Natural Cycles
was an indicator of the rising concerns regarding the mobile application’s
functionality and marketing scheme. In spite of the international skepticism,
critics will note that the FDA cleared Natural Cycles for marketing in the
United States.85 In an effort to progress its objectives of effectively regulating
digitalized health, the FDA adhered to its Digital Health Innovation Plan by
relaxing its review processes for these new devices that they deem to be at a
low-to-moderate risk level. In doing so, the FDA may be putting consumers
at risk by allowing the manufactures of these new devices to have a freer rein
on how they market. With a common understanding that consumers make
certain assumptions about what it means to be FDA approved, or cleared, it
can be alarming that in this new era of technological devices that review
standards would be lowered rather than raised. Critics who recognize this
issue are also aware of the complexities of the FDA processes and difficulties
consumers must have with parsing out the differences between what it means
to be “FDA Approved,” as governed by the PMA process, and “FDA
Cleared,” through the 510(k) premarket notification process.86 Thus, they
find that though this is a crucial area of innovation, it is equally important
that consumers are kept apprised of what these devices are and what they do
beyond just how they are marketed.
81. See Griswold, 381 U.S. at 494.
82. See id.
83. See id.
84. See generally Wetsman, supra note 5.
85. See Sheridan, supra note 44.
86. See McNamee, supra note 22.
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However, proponents of this quicker push for digital health and its pro-
motion to consumers through streamlined means argue that a mobile applica-
tion like Natural Cycles should be celebrated for providing greater
reproductive choice to women. By advancing sexual health technologically,
Natural Cycles is providing a “short-cut” for consumers and in that way cut-
ting costs while also providing efficiency and accessibility. Advocates for
maintaining this progression of digital health note the constitutional implica-
tions that shroud the efforts to cut back on clearing devices for public en-
gagement. The Fourteenth Amendment recognizes a fundamental,
unenumerated right to privacy which advocates have also found to be con-
nected to the right of reproductive choice for women.87 Persuasive arguments
have been, and will continue to be, expressed for both sides regarding this
topic of digital contraception, and the conversation of reproductive choice
will nevertheless persist as it has through the years. But taking a look through
the lense of the consumer, one can find the rather unnatural basis of these
mobile applications that tout that their accessibility provides the get-away
from hormones when, really, that accessibility is only providing more reli-
ance on the man-made device of a mobile phone.
87. See Griswold, 381 U.S. at 494.
